GSK has announced that its B7-H3-targeted antibody-drug conjugate (ADC), GSK'227, has received breakthrough therapy designation from the U.S. Food and Drug Administration (FDA) for the treatment of relapsed or refractory osteosarcoma. This rare and aggressive form of bone cancer currently has no approved treatments available after failure of two prior lines of therapy, highlighting a significant unmet medical need.
The breakthrough therapy designation, supported by data from the ARTEMIS-002 trial, underscores the potential of GSK'227 to provide a substantial clinical benefit over existing treatment options. Osteosarcoma is a challenging malignancy, and new therapeutic approaches are urgently needed to improve patient outcomes.
GSK'227 targets the B7-H3 protein, which is overexpressed in various cancers, including osteosarcoma. By delivering a cytotoxic payload directly to cancer cells expressing B7-H3, the ADC aims to selectively kill tumor cells while minimizing damage to healthy tissues. The ARTEMIS-002 trial is an ongoing study evaluating the safety and efficacy of GSK'227 in patients with advanced solid tumors, including osteosarcoma.
This FDA breakthrough therapy designation marks the third regulatory milestone for GSK'227. The drug has previously received similar designations in both Europe and the US for other cancer indications, reflecting its broad potential across different tumor types. The continued development of GSK'227 represents a promising avenue for addressing unmet needs in cancer therapy.
